TARS Antibody (1A9)

Immunohistochemistry-Paraffin: TARS Antibody (1A9) [H00006897-M01]

Immunohistochemistry-Paraffin: TARS Antibody (1A9) [H00006897-M01] - Analysis of monoclonal antibody to TARS on formalin-fixed paraffin-embedded human liver. Antibody concentration 3 ug/ml.

Immunohistochemistry: TARS Antibody (1A9) [H00006897-M01] -

Immunohistochemistry: TARS Antibody (1A9) [H00006897-M01] - TARS expression co-localized with VEGF & in leukocytes. Tissues were stained by IHC as in Figure 2. Shown are 40x images of serial sections stained with (A,B) No primary Ab as a negative control (C,D) TARS or (E,F) VEGF. Bottom panels show examples of TARS staining in infiltrating leukocytes. Bar = 50 μm. See Additional File 3 for supporting images. Image collected & cropped by CiteAb from the following publication (https://bmccancer.biomedcentral.com/articles/10.1186/1471-2407-14-620), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Immunohistochemistry: TARS Antibody (1A9) [H00006897-M01] -

Immunohistochemistry: TARS Antibody (1A9) [H00006897-M01] - TARS expression increases with stage of ovarian cancer. A. Tissues were stained for TARS by immunohistochemistry & counter-stained with Mayers’ hematoxylin. Images were scored blindly by 2 independent investigators & tumor identification was later confirmed by a pathologist (SLM). Shown are 10x images from (1) normal ovary & examples of TARS score increasing with extent of disease (2–4), Bar = 100 μm. B. Graph representing average scores where high stage is ≥ stage 3; statistical significance determined by one-way ANOVA. For more detailed statistics, see Table 1 for Pearson’s Correlations. C. Shown is a graph of individual patient TARS tumor scores grouped according to FIGO stage of disease (i.e. Stage 3.75 = FIGO 3C). Image collected & cropped by CiteAb from the following publication (https://bmccancer.biomedcentral.com/articles/10.1186/1471-2407-14-620), licensed under a CC-BY license. Not internally tested by Novus Biologicals.